MA53911A - Polythérapie contre le cancer - Google Patents
Polythérapie contre le cancerInfo
- Publication number
- MA53911A MA53911A MA053911A MA53911A MA53911A MA 53911 A MA53911 A MA 53911A MA 053911 A MA053911 A MA 053911A MA 53911 A MA53911 A MA 53911A MA 53911 A MA53911 A MA 53911A
- Authority
- MA
- Morocco
- Prior art keywords
- polytherapy
- against cancer
- cancer
- polytherapy against
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862745464P | 2018-10-15 | 2018-10-15 | |
US201962802091P | 2019-02-06 | 2019-02-06 | |
US201962854494P | 2019-05-30 | 2019-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53911A true MA53911A (fr) | 2022-01-19 |
Family
ID=68393113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053911A MA53911A (fr) | 2018-10-15 | 2019-10-15 | Polythérapie contre le cancer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210332137A1 (fr) |
EP (1) | EP3867274A1 (fr) |
JP (2) | JP7448552B2 (fr) |
KR (1) | KR20210076025A (fr) |
CN (1) | CN113166242A (fr) |
AU (1) | AU2019361923A1 (fr) |
BR (1) | BR112021007134A2 (fr) |
CA (1) | CA3114955A1 (fr) |
IL (1) | IL282093A (fr) |
MA (1) | MA53911A (fr) |
MX (1) | MX2021004226A (fr) |
SG (1) | SG11202103153VA (fr) |
TW (1) | TWI835885B (fr) |
WO (1) | WO2020081497A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202000387YA (en) | 2017-08-25 | 2020-03-30 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
WO2022039490A1 (fr) * | 2020-08-18 | 2022-02-24 | Abl Bio, Inc. | Anticorps bispécifiques anti-b7-h4/anti-4-1bb et leurs utilisations |
CA3203721A1 (fr) | 2021-01-04 | 2022-07-07 | Timothy B. Lowinger | Conjugues anticorps-medicament ciblant b7-h4 et leurs methodes d'utilisation |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
EP2270150B2 (fr) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
CA2412701A1 (fr) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Procede de production de glycoproteines modifiees |
MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002030954A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Procede de purification d'un anticorps |
MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
CA2838062C (fr) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps |
EP1485486B1 (fr) | 2002-03-19 | 2012-11-21 | Stichting Dienst Landbouwkundig Onderzoek | Optimisation du traitement du glycane chez les plantes |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
DE602004028337D1 (de) | 2003-01-22 | 2010-09-09 | Glycart Biotechnology Ag | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion |
EP1888649A2 (fr) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc |
KR20080094064A (ko) | 2006-01-17 | 2008-10-22 | 바이오렉스 쎄라퓨틱스, 인코포레이티드 | 식물에서 n-글리칸의 인간화 및 최적화 조성물 및 방법 |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
PL2170959T3 (pl) * | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
CA2706926A1 (fr) * | 2007-11-30 | 2009-06-11 | Bristol-Myers Squibb Company | Conjugues anticorps monoclonal-medicaments anti-b7h4 et procedes d'utilisation associes |
CN103476795B (zh) | 2011-03-29 | 2016-07-06 | 罗切格利卡特公司 | 抗体Fc变体 |
US9562099B2 (en) * | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
WO2015017600A1 (fr) | 2013-08-01 | 2015-02-05 | Five Prime Therapeutics, Inc. | Anticorps anti-fgfr2iiib afucosylés |
CN113698485A (zh) * | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
WO2016070001A1 (fr) * | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Méthodes de traitement d'états pathologiques avec des anticorps qui se lient à b7-h4 |
IL278423B2 (en) * | 2015-02-26 | 2024-04-01 | Merck Patent Gmbh | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment |
CN108495651A (zh) * | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
WO2018106862A1 (fr) * | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
JP7106538B2 (ja) * | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
SG11202000387YA (en) * | 2017-08-25 | 2020-03-30 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
BR112020016990A2 (pt) * | 2018-02-21 | 2021-02-23 | Five Prime Therapeutics, Inc. | regimes de dosagem de anticorpos contra b7-h4 |
-
2019
- 2019-10-15 AU AU2019361923A patent/AU2019361923A1/en active Pending
- 2019-10-15 JP JP2021545279A patent/JP7448552B2/ja active Active
- 2019-10-15 KR KR1020217012944A patent/KR20210076025A/ko unknown
- 2019-10-15 MX MX2021004226A patent/MX2021004226A/es unknown
- 2019-10-15 EP EP19795757.4A patent/EP3867274A1/fr active Pending
- 2019-10-15 MA MA053911A patent/MA53911A/fr unknown
- 2019-10-15 BR BR112021007134-2A patent/BR112021007134A2/pt unknown
- 2019-10-15 CA CA3114955A patent/CA3114955A1/fr active Pending
- 2019-10-15 CN CN201980071763.6A patent/CN113166242A/zh active Pending
- 2019-10-15 SG SG11202103153VA patent/SG11202103153VA/en unknown
- 2019-10-15 TW TW108137035A patent/TWI835885B/zh active
- 2019-10-15 WO PCT/US2019/056210 patent/WO2020081497A1/fr unknown
-
2021
- 2021-04-06 IL IL282093A patent/IL282093A/en unknown
- 2021-04-07 US US17/224,865 patent/US20210332137A1/en active Pending
-
2024
- 2024-02-29 JP JP2024030048A patent/JP2024059913A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112021007134A2 (pt) | 2021-08-10 |
JP2024059913A (ja) | 2024-05-01 |
SG11202103153VA (en) | 2021-04-29 |
IL282093A (en) | 2021-05-31 |
US20210332137A1 (en) | 2021-10-28 |
CA3114955A1 (fr) | 2020-04-23 |
EP3867274A1 (fr) | 2021-08-25 |
JP2022513350A (ja) | 2022-02-07 |
WO2020081497A1 (fr) | 2020-04-23 |
JP7448552B2 (ja) | 2024-03-12 |
TWI835885B (zh) | 2024-03-21 |
CN113166242A (zh) | 2021-07-23 |
KR20210076025A (ko) | 2021-06-23 |
AU2019361923A1 (en) | 2021-06-03 |
MX2021004226A (es) | 2021-07-15 |
TW202027783A (zh) | 2020-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52090A (fr) | Polythérapie | |
MA47676A (fr) | Polythérapie | |
MA48728A (fr) | Polythérapie contre le cancer de la prostate | |
MA53911A (fr) | Polythérapie contre le cancer | |
MA49921A (fr) | Polythérapie | |
GB201800733D0 (en) | Cancer | |
MA42609A (fr) | Polythérapie contre le cancer | |
GB201814487D0 (en) | Cancer | |
DK3752258T3 (da) | Trampolin | |
DK3587968T3 (da) | Fluidsystem | |
DOS2019000013S (es) | Logo | |
MA49925A (fr) | Claie | |
DE112019000442A5 (de) | Ringtilgereinrichtung | |
NO20181678A1 (no) | Rissanviser | |
JP1628556S (ja) | たい焼 | |
JP1628555S (ja) | たい焼 | |
UA39481S (uk) | Антена логаріфмічно-періодична | |
ES1218724Y (es) | Terrario | |
UA38585S (uk) | Електролобзик | |
UA38411S (uk) | Термокухоль | |
UA38602S (uk) | Термокухоль | |
UA38633S (uk) | Електролобзик | |
UA38632S (uk) | Електролобзик | |
UA38581S (uk) | Термокухоль | |
UA38582S (uk) | Термокухоль |